<DOC>
	<DOCNO>NCT01396148</DOCNO>
	<brief_summary>Children young adult gastrointestinal stromal tumor ( GIST ) treat sunitinib . The safety ( include pharmacokinetics ) tolerability sunitinib study patient . In addition , tumor response overall survival assess .</brief_summary>
	<brief_title>A Study Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histological diagnosis GIST . Patients must demonstrate either disease progression intolerance imatinib mesylate , nonmutant Stem Cell Factor Receptor gene ( KIT ) GIST , obtain imatinib country Measurable Response Evaluation Criterion Solid Tumors ( RECIST ) evaluable disease . Current treatment another investigational agent . Prior sunitinib treatment . Prior therapy know risk cardiovascular complication .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Children young adult GIST</keyword>
	<keyword>sunitinib malate</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tumor response</keyword>
	<keyword>overall survival</keyword>
	<keyword>tumor KIT mutation status</keyword>
</DOC>